Request a Proposal  

Pharm-Olam Blog


Pharm-olam is a global clinical research organization that delivers right-sized trial services to pharmaceutical, biotechnology, government, and public health organizations around the world.

Blog Feature

Rare & Orphan Disease

By: Pharm-Olam
October 30th, 2018

Houston, Oct. 30, 2018 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Pharm-Olam is proud to have contributed to the execution and completion of its pivotal Phase III study.